The treatment of acute leukaemia

Lancet

Volumn 349, Issue 9047, 1997, Pages 270-275

  Burnett, A K ^a   Eden, O B ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; BONE MARROW TRANSPLANTATION; CHILD; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; PRIORITY JOURNAL; REVIEW;

EID: 0031031598     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)08086-5     Document Type: Note

References (40)

1. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukaemia. Blood 1991; 71: 1666-74.
2. Arlin Z, Delvyn C, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitozantrone to daunorubicin in previously untreated adult patients with acute non-lymphocytic leukaemia (ANLL). Leukaemia 1990; 4: 177-83.
3. Wheatley K. Meta-analysis of randomised trials of idarubicin (IDAR) or mitozantrone (MTO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukaemia. Blood 1995; 86: 434a.
4. Rees JKH, Gray RG, Wheatley K. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council AML9 study. Br J Haematol 1996; 94: 89-98.
5. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukaemia. Blood 1996; 87: 1710-17.
6. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR Jr. Prognostic impact of cytogenetic abnormalities in patients with de novo acute non-lymphocytic leukemia. Blood 1989; 73: 263-70.
7. Yunis JJ, Brunning RD, Howe RB, Lobell M. High-resolution chromosomes as an independent prognostic indicator in adult acute non-lymphocytic leukemia. N Engl J Med 1984; 311: 812-18.
8. Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403-12.
9. Lowenberg B, van Putten WL, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993; 328: 614-19.
10. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-96.
11. Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myeloid leukemia. Blood 1993; 81: 3083-90.
12. Wormann B, Safford M, Konemann S, et al. Prospective study on the clinical relevance of residual disease in patients with acute myeloid leukemia in complete remission. Hematol Blood Transf 1994; 36: 5-80.
13. Appelbaum FR, Fischer LD, Thomas D, et al. Chemotherapy versus marrow transplantation for adults with acute non-lymphocytic leukemia: a five-year follow up. Blood 1988; 72: 179-84.
14. Begg CB, McGlave PB, Bennett JM, Cassileth PA, Oxen MM. A critical comparison of allogenic bone marrow transplantation and conventional chemotherapy as treatment for acute non-lymphocytic leukemia. J Clin Oncol 1984; 2: 369-78.
15. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896-942.
16. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217-23.
17. Burnett AK, Goldstone AH, Stevens R, et al. Allo and auto bone marrow transplant reduce relapse risk in AML in CR1 but do not significantly improve overall survival: results of the MRC AML 10 trial. Br J Haematol 1996; 93 (suppl 2): 313.
18. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996; 334: 1428-34.
19. Woods WG, Kobrinsky N, Buckley J, et al. Timing intensive induction therapy improves post-remission outcome in acute myeloid leukemia (AML) irrespective of the use of bone marrow transplantation (BMT). Blood 1994; 84 (suppl 1): 232a.
20. Demirer T, Buckner CD, Appelbaum FR, et al. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia. Bone Marrow Transplant 1995; 15: 915-22.
21. Gale RP, Horowitz MM, Weiner RS, et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203-08.
22. Ruutu T, Almqvist A, Hallman H, et al. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine and idarubicin in elderly patients: a randomized comparison with 5-day T AD. Leukemia 1994; 8: 11-15.
23. Pirker R, Wallner J, Geissler K, et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Institute 1991; 83: 708-12.
24. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (MDR1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood. 1991; 78: 586-92.
25. Rowe JM. Use of growth factors during induction therapy for acute myeloid leukemia. Leukemia 1996; 10: S40-S43.
26. Eden OB, Lilleyman J, Richards S, et al. Results of the MRC UKALL VIII protocol - report to the Medical Research Council. Br J Haematol 1990; 78: 187-96.
27. Veerman AJP, Hahlen K, Kamps WA, et al. Dutch Childhood Leukaemia Study Group: early results of study VI (1984-88). Haematol Blood Transf 1990; 33: 413-11.
28. Biondi A, Yokata S, Hansen-Hagge TE, et al. Minimal residual disease in childhood acute lymphoblastic leukaemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukaemia 1992; 6: 282-88.
29. Chessells JM, Bailey C, Richards SM, for the Medical Research Council Working Party on Childhood Leukaemia. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet 1995; 345: 143-48.
30. Chessells JM, Hall E, Prentice HG, et al. The impact of age on outcome in lymphoblastic leukaemia MRC UKALL X and XA compared. J Clin Oncol (in press).
31. Patte C, Levergen G, Robert A, et al. Results of the LMB 89 protocol on B-cell leukaemia: a study of the S.F.O.P. Med Pediatr Oncol 1992; 20: 405.
32. Aur RJ, Simone J, Hustu HO, et al. CNS therapy and combination chemotherapy of childhood lymphocytic leukaemia. Blood 1971; 37: 272-81.
33. Whitehead VM, Vuchich MJ, Lauer SJ, et al. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage ALL. A Pediatric Oncology Group Study. Blood 1992; 80: 1316.
34. Kaspars GJL, Smets LA, Pieters R, et al. Favourable prognosis of hyperdiploid common ALL may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995; 85: 751.
35. Goker E, Lin JT, Trippett T, et al. Decreased polyglutamylation of methotrexate in ALL blasts in adults compared to children with this disease. Leukaemia 1993; 7: 1000.
36. Maung ZT, Reid MM, Matheson E, et al. Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with ALL. Br J Haematol 1995; 91: 93.
37. Greaves MF. Stem cell origins of leukaemia and curability. Br J Cancer 1993; 67: 413.
38. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukaemia in adults. Blood 1995; 85: 1151.
39. Nachman J, Sather HN, Buckley JD, et al. Young adults 16-21 years of age at diagnosis entered on childrens' cancer group acute lymphoblastic leukaemia and acute myeloblastic leukemia protocols. Cancer 1993; 71: 3377.
40. Gale RP, Kersey JH, Bortin MM, et al. Bone marrow transplantation for acute lymphoblastic leukaemia. Lancet 1983; ii: 663-67.